Literature DB >> 10433282

CT measurement of perfusion and permeability within lymphoma masses and its ability to assess grade, activity, and chemotherapeutic response.

P E Dugdale1, K A Miles, I Bunce, B B Kelley, D A Leggett.   

Abstract

PURPOSE: Structural CT criteria such as nodal size and appearance have a poor correlation with the grade and activity of a lymphoma mass. This study investigates the potential for functional CT perfusion and permeability measurements to assess lymphoma grade and activity.
METHOD: Thirty-nine patients with proven lymphoma underwent 47 dynamic contrast-enhanced CT studies. Lymphoma grade was classified as low or intermediate/high. In seven patients who underwent repeated studies, measurements were correlated against change in disease activity in the intervening period.
RESULTS: Median perfusion values were higher in active disease (0.55 vs. 0.37 ml/min/ml) and intermediate/high-grade lymphoma (0.56 vs. 0.46 ml/min/ml). Perfusion below 0.2 ml/min/ml implied inactive disease (p < 0.03), whereas > 0.5 ml/min/ml suggested intermediate/high-grade lymphoma (p = 0.11). Median values of permeability were little different between patient groups. Only perfusion fell when disease became inactive.
CONCLUSION: Only CT perfusion measurements of nodes have potential for assessing lymphoma grade, activity, and treatment response.

Entities:  

Mesh:

Year:  1999        PMID: 10433282     DOI: 10.1097/00004728-199907000-00010

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  27 in total

Review 1.  Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma.

Authors:  Sarah J Vinnicombe; Rodney H Reznek
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-23       Impact factor: 9.236

Review 2.  Assessment of response to therapy using conventional imaging.

Authors:  Sheila C Rankin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-27       Impact factor: 9.236

3.  Radiation dose reduction in computed tomography: techniques and future perspective.

Authors:  Lifeng Yu; Xin Liu; Shuai Leng; James M Kofler; Juan C Ramirez-Giraldo; Mingliang Qu; Jodie Christner; Joel G Fletcher; Cynthia H McCollough
Journal:  Imaging Med       Date:  2009-10

Review 4.  [Inflammatory lesions of the brainstem and the cerebellopontine angle].

Authors:  J Lutz; L Jäger
Journal:  Radiologe       Date:  2006-03       Impact factor: 0.635

5.  Renal perfusion and hemodynamics: accurate in vivo determination at CT with a 10-fold decrease in radiation dose and HYPR noise reduction.

Authors:  Xin Liu; Andrew N Primak; James D Krier; Lifeng Yu; Lilach O Lerman; Cynthia H McCollough
Journal:  Radiology       Date:  2009-10       Impact factor: 11.105

6.  Imaging characteristics of primary laryngeal lymphoma.

Authors:  N A Siddiqui; Barton F Branstetter; B E Hamilton; L E Ginsberg; C M Glastonbury; H R Harnsberger; E L Barnes; E N Myers
Journal:  AJNR Am J Neuroradiol       Date:  2010-04-01       Impact factor: 3.825

7.  The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients.

Authors:  Martijn R Meijerink; Hester van Cruijsen; Klaas Hoekman; Matthijs Kater; Cors van Schaik; Jan Hein T M van Waesberghe; Giuseppe Giaccone; Radu A Manoliu
Journal:  Eur Radiol       Date:  2006-10-27       Impact factor: 5.315

8.  Correlation of histological findings from a large ciliochoroidal melanoma with CT perfusion and 3T MRI dynamic enhancement studies.

Authors:  Jose S Pulido; Norbert G Campeau; Ernst Klotz; Andrew N Primak; Osama Saba; Kaan Gunduz; Herbert Cantrill; Diva Salomão; Cynthia H McCollough
Journal:  Clin Ophthalmol       Date:  2008-06

Review 9.  CT perfusion in oncology: how to do it.

Authors:  G Petralia; L Bonello; S Viotti; L Preda; G d'Andrea; M Bellomi
Journal:  Cancer Imaging       Date:  2010-02-11       Impact factor: 3.909

10.  Molecular and clinical aspects of targeting the VEGF pathway in tumors.

Authors:  Grzegorz Korpanty; Laura A Sullivan; Elizabeth Smyth; Desmond N Carney; Rolf A Brekken
Journal:  J Oncol       Date:  2010-06-10       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.